Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2016

View Archived Issues

Zinc-13407541 partially reverses hypophosphatemic effects of excess FGF-23 in vivo

Janssen initiates phase IIb study of simeprevir, odalasvir and AL-335 for HCV

IL-31 levels are upregulated in dermatomyositis

PRMT5 inhibitors could represent new therapeutic approach in treatment of psoriatic diseases

Hetero Research Foundation patents antiviral agents

Blueprint Medicines reports data from ongoing phase I trial of BLU-554 in HCC

FDA gives fast track designation to Epizyme's tazemetostat

Sichuan Haisco Pharmaceutical discloses M3 receptor antagonist and/or beta2-adrenoreceptor agonists

Bristol-Myers Squibb describes bromodomain inhibitors

FDA accepts sBLA for Keytruda in patients with MSI-H cancer

Kancera develops HDAC inhibitors

European Commission approves Glyxambi for type 2 diabetes

Phase II trial of cavosonstat in cystic fibrosis does not meet primary endpoint

EMA grants full aproval to vismodegib

Oxford BioMedica establishes strategic alliance with Orchard Therapeutics

Mutations in FAM105B gene may be involved in autoinflammatory diseases

GTx's enobosarm achieves primary efficacy endpoint in phase II trial

Inisync available in Japan

Idera and Vivelix sign license and collaboration agreement for IMO-9200

MonoSol files NDA with FDA for Tadalafil PharmFilm in the treatment of erectile dysfunction

Cyfip2 is a genome-wide significant genetic factor for binge eating

Galapagos initiates phase I study of GLPG-2737 in cystic fibrosis

Relypsa's patiromer gains FDA approval of sNDA, black box warning removed from label

Recro Pharma discloses positive results from phase III trial of i.v. meloxicam

VB-037 shows promise in EAE model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...